Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -86.49% | -98.62% | -16.67% | -76.19% | 133.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.49% | -98.62% | -16.67% | -76.19% | 133.64% |
| Cost of Revenue | 16.99% | 7.70% | 59.62% | 24.57% | -11.84% |
| Gross Profit | -17.21% | -9.83% | -59.66% | -24.69% | 12.53% |
| SG&A Expenses | 17.50% | 10.08% | 17.54% | 17.24% | 13.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.09% | 8.17% | 48.50% | 23.04% | -7.58% |
| Operating Income | -17.27% | -9.88% | -48.53% | -23.14% | 8.18% |
| Income Before Tax | 26.74% | -10.52% | -53.42% | -21.52% | -46.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.74% | -10.52% | -53.42% | -21.52% | -46.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.74% | -10.52% | -53.42% | -21.52% | -46.08% |
| EBIT | -17.27% | -9.88% | -48.53% | -23.14% | 8.18% |
| EBITDA | -17.75% | -10.31% | -49.22% | -23.36% | 6.81% |
| EPS Basic | 39.92% | 16.61% | -9.66% | 13.98% | -25.03% |
| Normalized Basic EPS | 1.12% | 16.60% | -9.65% | 13.98% | 24.02% |
| EPS Diluted | 39.92% | 16.61% | -9.66% | 13.98% | -22.68% |
| Normalized Diluted EPS | 1.12% | 16.60% | -9.65% | 13.98% | 24.02% |
| Average Basic Shares Outstanding | 21.93% | 32.54% | 39.91% | 41.25% | 16.82% |
| Average Diluted Shares Outstanding | 21.93% | 32.54% | 39.91% | 41.25% | 16.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
